Editas Medicine

Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
BioSpace
gene editing
Editas Medicine
Vertex Pharmaceuticals
CRISPR Therapeutics
EDIT-301
sickle cell disease
beta thalassemia
Flag link:
Gene Editing Therapeutics Could Hit the Market in 2023
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Flag link:
Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Flag link:
Editas, in next restructuring step, to sell cell therapy work to Shoreline
Editas, in next restructuring step, to sell cell therapy work to Shoreline
BioPharma Dive
Editas Medicine
natural killer cell therapy
Shoreline Biosciences
Flag link:
Editas finds buyer for iNK programs 10 days after clearing out pipeline
Editas finds buyer for iNK programs 10 days after clearing out pipeline
Fierce Biotech
Editas Medicine
iNK
Shoreline Biosciences
Flag link:
Editas edits pipeline, lays off 20% and says bye to CSO to kick off #JPM23 
Editas edits pipeline, lays off 20% and says bye to CSO to kick off #JPM23 
Endpoints
JPMHC 2023
Editas Medicine
layoffs
Flag link:
Editas teases tiny sickle cell sample in effort to climb back into gene editing's upper echelon
Editas teases tiny sickle cell sample in effort to climb back into gene editing's upper echelon
Fierce Biotech
Editas Medicine
sickle cell disease
gene editing
EDT-301
Flag link:
Where Will Editas Medicine Be in 1 Year?
Where Will Editas Medicine Be in 1 Year?
Motley Fool
Editas Medicine
EDIT-101
Leber's congenital amaurosis
Flag link:
Editas halts lead CRISPR program after efficacy data underwhelm
Editas halts lead CRISPR program after efficacy data underwhelm
Endpoints
Editas Medicine
CRISPR
EDIT-101
clinical trials
Flag link:
ASH preview – waiting for Editas
ASH preview – waiting for Editas
EP Vantage
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
Flag link:
Editas Awaits Data to Determine the Future of Ophthalmic Gene Therapy, EDIT-101
Editas Awaits Data to Determine the Future of Ophthalmic Gene Therapy, EDIT-101
BioSpace
Editas Medicine
EDIT-101
gene therapy
Leber's congenital amaurosis
Flag link:
Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets
Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets
BioSpace
Editas Medicine
gene editing
CRISPR
M&A
oncology
Flag link:
Editas treats first patient in sickle cell trial as FDA lifts partial hold
Editas treats first patient in sickle cell trial as FDA lifts partial hold
BioPharma Dive
Editas Medicine
clinical trials
CRISPR
gene editing
sickle cell disease
Flag link:
Editas’ Novel Sickle Cell Therapeutic Shows Early Promise
Editas’ Novel Sickle Cell Therapeutic Shows Early Promise
BioSpace
Editas Medicine
clinical trials
EDIT-301
sickle cell disease
Flag link:
Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy
Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy
BioPharma Dive
Editas Medicine
CRISPR
gene editing
Immatics
gamma delta cell therapy
Flag link:
FDA tags Editas' thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic
FDA tags Editas' thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic
Fierce Biotech
Editas Medicine
FDA
beta thalassemia
EDIT-301
Flag link:
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder
Fierce Biotech
Editas Medicine
EDIT-301
CRISPR
beta thalassemia
Flag link:
Editas' gene-editing data has company touting prime time based on early vision improvement signals but questions remain
Editas' gene-editing data has company touting prime time based on early vision improvement signals but questions remain
Fierce Biotech
CRISPR
Editas Medicine
gene editing
EDIT-101
vision loss
Flag link:
Will Moderna Buy Editas Medicine to Jump Into Gene Editing?
Will Moderna Buy Editas Medicine to Jump Into Gene Editing?
Motley Fool
Moderna Therapeutics
gene editing
Editas Medicine
M&A
Flag link:

Pages